While rates of HIV have been declining, other sexually transmitted diseases have become more prevalent in recent years.

The Medical Supply Chain Resiliency Act would allow the establishment of trusted trade partnerships to diversify the sourcing and procurement of medical devices as well as pharmaceuticals.

The pharmaceutical industry has an opportunity to move production onshore. It should take it.

Medical supply chains are experiencing a "severe" shortage of cancer drugs after carboplatin and cisplatin were reportedly found to be in “extremely short supply.”

The trend comes in part from the U.S.-Mexico-Canada Agreement (USMCA), which took effect in July 2020 as a replacement for the North American Free Trade Agreement.

The pharmaceutical sector has come under ever-greater scrutiny in recent years, as more and more counterfeit products infiltrate legitimate supply chains.

Life sciences companies need to draw on the tools and protections in their supplier contracts to maintain continuity and minimize disruption.

The importation of fake and fraudulent medical supplies must be stopped.

Companies make thousands of decisions a day about what to produce, where to put product and what to promote. But they often make those decisions based on very limited information.